Edition:
United States

Oxford BioMedica PLC (OXB.L)

OXB.L on London Stock Exchange

8.90GBp
3:43am EDT
Change (% chg)

-0.08 (-0.89%)
Prev Close
8.98
Open
9.00
Day's High
9.00
Day's Low
8.90
Volume
183,692
Avg. Vol
11,653,528
52-wk High
11.50
52-wk Low
2.98

Latest Key Developments (Source: Significant Developments)

Oxford Biomedica says Stuart Paynter joins group as CFO
Tuesday, 29 Aug 2017 02:00am EDT 

Aug 29 (Reuters) - Oxford Biomedica Plc :STUART PAYNTER TODAY JOINS GROUP AS CHIEF FINANCIAL OFFICER AND MEMBER OF BOARD OF DIRECTORS.TIM WATTS, OUTGOING CFO WILL REMAIN UNTIL 29 SEPTEMBER 2017 AT WHICH POINT HE WILL STEP DOWN FROM BOARD AND LEAVE GROUP.  Full Article

Oxford Biomedica completes new $55 million debt facility
Friday, 30 Jun 2017 05:38am EDT 

June 30 (Reuters) - Oxford Biomedica Plc ::Completed a new $55 million debt facility with Oaktree Capital Management - Strategic Credit Strategy.Facility has been used to redeem existing debt facility with Oberland Capital Healthcare.  Full Article

Oxford Biomedica notes acceptance by FDA of a biologics license application filing for CTL019
Thursday, 30 Mar 2017 02:02am EDT 

Oxford Biomedica Plc : Oxford Biomedica notes acceptance by FDA of a biologics license application (BLA) filing for CTL019 .Oxford Biomedica will also receive undisclosed royalties on potential future sales of Novartis Car-T products..  Full Article

Oxford biomedica says FY EBITDA loss reduced to £7.1 mln
Thursday, 16 Mar 2017 03:13am EDT 

Oxford Biomedica Plc : Fy EBITDA loss reduced to £7.1 million .Fy gross income increased by 64% to £30.8 million.  Full Article

Oxford biomedica says Trovax shown to induce beneficial anti-tumour immune responses
Friday, 24 Feb 2017 02:28am EST 

Oxford Biomedica Plc : Cyclophosphamide and Trovax independently shown to induce highly beneficial anti-tumour immune responses .Both drugs resulting in significantly prolonged survival of advanced colorectal cancer patients.  Full Article

Oxford Biomedica says Chief Development Officer Blake to leave in Aug
Thursday, 12 May 2016 02:11am EDT 

Oxford Biomedica Plc : Announces that Dr Paul Blake will leave group when his current contract expires at end of August 2016. .Blake was appointed to Oxford Biomedica's board as a non-executive director in January 2010 and subsequently he became chief development officer in September 2014..  Full Article

RPT-Profit on $475,000 Novartis cancer drug could be a while coming

ZURICH, Aug 31 Novartis's new gene-modifying cancer therapy's $475,000-per-patient sticker price has drawn fire from advocate groups calling for cheaper drugs, but analysts said the Swiss drugmaker could initially struggle to break even.